Elite in HIV/AIDS

Olivier Lambotte

Paris, FR 
Elite in HIV/AIDS
Paris, FR 
OverviewLocationsClinical Research

Overview

Olivier Lambotte practices in Paris, France. Mr. Lambotte is rated as an Elite expert by MediFind in the treatment of HIV/AIDS. His top areas of expertise are HIV/AIDS, Hemophagocytic Lymphohistiocytosis, Purpura, Splenectomy, and Thymectomy.

His clinical research consists of co-authoring 344 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 117 articles in the study of HIV/AIDS.

Gender
Male

Locations

Paris, France
Other Locations
Fontenay-sous-bois, 92265, France
94275, France
Université Paris Est Créteil, Creteil, France
Dijon, France
Roussy-le-village, 94805, France
Villejuif, France
Montigny-sur-loing, France
CHRU de Montpellier
Montpellier, France
63 Rue Gabriel Peri, Rouez, 94270, France
Orsay, France
Lille, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)
Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)
Enrollment Status: Completed
Publish Date: October 06, 2025
Intervention Type: Drug
Study Drugs: Steroid, Cyclophosphamide, Rituximab
Study Phase: Phase 3
Sub-cutaneous Rituximab-miniCHOP Versus Sub-cutaneous Rituximab-miniCHOP + Lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More. A Multicentric Phase III Study of the LYSA Association
Sub-cutaneous Rituximab-miniCHOP Versus Sub-cutaneous Rituximab-miniCHOP + Lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More. A Multicentric Phase III Study of the LYSA Association
Enrollment Status: Completed
Publish Date: April 13, 2021
Intervention Type: Drug
Study Drugs: Lenalidomide, Rituximab
Study Phase: Phase 3
Randomized Phase III Study Evaluating the Non-inferiority of a Treatment Adapted to the Early Response Evaluated With 18F-FDG PET Compared to a Standard Treatment, for Patients Aged From 18 to 80 Years With Low Risk (aa IPI = 0) Diffuse Large B-cells Non Hodgkin's Lymphoma CD 20+
Randomized Phase III Study Evaluating the Non-inferiority of a Treatment Adapted to the Early Response Evaluated With 18F-FDG PET Compared to a Standard Treatment, for Patients Aged From 18 to 80 Years With Low Risk (aa IPI = 0) Diffuse Large B-cells Non Hodgkin's Lymphoma CD 20+
Enrollment Status: Completed
Publish Date: July 14, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

344 Total Publications

Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockade.
Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockade.
Journal: Journal for immunotherapy of cancer
Published: August 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lambotte's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 88 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile